YU35996A - Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže - Google Patents

Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže

Info

Publication number
YU35996A
YU35996A YU35996A YU35996A YU35996A YU 35996 A YU35996 A YU 35996A YU 35996 A YU35996 A YU 35996A YU 35996 A YU35996 A YU 35996A YU 35996 A YU35996 A YU 35996A
Authority
YU
Yugoslavia
Prior art keywords
primatized
monkey
monoclonal antibodies
antibodies
human
Prior art date
Application number
YU35996A
Other languages
English (en)
Inventor
R. Anderson Darrell
Brams Peter
Hanna Nabic
S. Shestowsky William
Original Assignee
Idec Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corporation filed Critical Idec Pharmaceuticals Corporation
Publication of YU35996A publication Critical patent/YU35996A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Predmetni pronalazak se odnosi na identifikaciju majmunskih antitela za humani B7.1 i B7.2 testiranjem biblioteka faga ili pomoću majmunskog hibridoma dobijenog koristeći B limfocite iz B7.1 i/ili B7.2 imuniziranih majmuna. Specifičnije, pronalazak obezbeđuje četiri majmunska monoklonalna antitela 7B6, 16C10, 7C10 i 20C9 koja inhibiraju B7:CD28 interakciju i deluju kao efikasni imunosupresanti. Pronalazak dalje obezbeđuje potpune DNA i amino kiselinske sekvence lakog i teškog lanca tri primatizovana antitela izvedena iz onih majmunskih monoklonalnih antitela koja vezuju B7.1 i moguće B7.2, primatizovano 7C10, primatizovano 7B6 i primatizovano 16C10. Ova primatizovana i majmunska antitela mogu biti korišćena kao specifični imunosupresanti, npr. za tretiranje autoimunih obolenja i prevenciju odbacivanja transplatiranog organa.
YU35996A 1995-06-07 1996-06-07 Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže YU35996A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,550 US6113898A (en) 1995-06-07 1995-06-07 Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies

Publications (1)

Publication Number Publication Date
YU35996A true YU35996A (sh) 1998-12-23

Family

ID=23936199

Family Applications (1)

Application Number Title Priority Date Filing Date
YU35996A YU35996A (sh) 1995-06-07 1996-06-07 Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže

Country Status (25)

Country Link
US (4) US6113898A (sh)
EP (2) EP1914301A1 (sh)
JP (1) JP4242451B2 (sh)
KR (1) KR100496307B1 (sh)
CN (2) CN101367877A (sh)
AR (2) AR001288A1 (sh)
AT (1) ATE384125T1 (sh)
AU (1) AU707023B2 (sh)
BR (1) BR9609035A (sh)
CA (1) CA2223532C (sh)
CO (1) CO4480111A1 (sh)
DE (1) DE69637408T2 (sh)
DK (1) DK0837927T3 (sh)
ES (1) ES2301169T3 (sh)
HK (1) HK1015413A1 (sh)
IL (1) IL122370A (sh)
MY (1) MY136224A (sh)
NO (1) NO328554B1 (sh)
NZ (1) NZ311904A (sh)
PT (1) PT837927E (sh)
SA (1) SA96170473B1 (sh)
UY (1) UY24256A1 (sh)
WO (1) WO1996040878A1 (sh)
YU (1) YU35996A (sh)
ZA (1) ZA964547B (sh)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2243459C (en) 1996-02-09 2002-09-17 Basf Aktiengesellschaft Human antibodies that bind human tnf.alpha.
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
BR9713498A (pt) * 1996-11-08 2000-02-29 Idec Pharma Corp Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos
CA2292415A1 (en) * 1997-06-20 1998-12-30 Innogenetics N.V. B7-binding molecules for treating immune diseases
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
HUP0201009A2 (en) 1999-05-07 2002-07-29 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
CN1373672A (zh) * 1999-07-12 2002-10-09 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
SE9903895D0 (sv) * 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001249182A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
CN1981868A (zh) 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
US6379900B1 (en) 2000-05-09 2002-04-30 Conceptual Mindworks, Inc. Compositions and methods of use of 8-nitroguanine
EP1294391B1 (en) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Combination of agents for inhibiting transplant rejection
EP2052742A1 (en) * 2000-06-20 2009-04-29 Biogen Idec Inc. Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
CN1318086C (zh) 2000-07-03 2007-05-30 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4分子用于制备治疗风湿性疾病的药物组合物中的用途
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
MXPA03006699A (es) * 2001-01-26 2004-05-31 Univ Emory Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US6955717B2 (en) * 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
EA007905B1 (ru) 2001-11-16 2007-02-27 Байоджен Айдек Инк. Полицистронная экспрессия антител
PT1485127E (pt) 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US7563771B2 (en) * 2002-11-13 2009-07-21 Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein E
SG144925A1 (en) * 2003-08-04 2008-08-28 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule
WO2005040384A1 (en) * 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
EP1692174A2 (en) * 2003-11-07 2006-08-23 Amgen Inc. Monkey immunoglobulin sequences
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN100369931C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人b7-1分子单克隆抗体及其应用
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
DK2195331T3 (da) 2007-08-28 2014-02-03 Uab Research Foundation Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
EP2769728A1 (en) 2007-09-04 2014-08-27 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP3062106B1 (en) 2008-04-16 2020-11-11 The Johns Hopkins University Method for determining androgen receptor variants in prostate cancer
JP5697268B2 (ja) 2009-09-29 2015-04-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ バッファー溶質のろ過前調整方法
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
EP2536432B1 (en) 2010-02-19 2018-08-08 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
MY191929A (en) 2010-06-03 2022-07-18 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
DK2580240T3 (en) 2010-06-14 2019-03-25 Lykera Biomed S A S100A4 ANTIBODIES AND THERAPEUTIC APPLICATIONS THEREOF
AU2011282476B2 (en) 2010-07-20 2015-08-20 Cephalon Australia Pty Ltd Anti-IL-23 heterodimer specific antibodies
WO2012061074A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
CA2817418A1 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
DK2665746T3 (en) 2011-01-17 2021-02-01 Lykera Biomed S A Antibodies against the s100p protein for the treatment and diagnosis of cancer
WO2012100835A1 (en) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Methods and compositions for the treatment of aids
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US20140314744A1 (en) 2011-06-06 2014-10-23 Neotope Biosciences Limited Mcam antagonists and methods of treatment
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP2014531210A (ja) 2011-09-30 2014-11-27 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ＴＬ１ａに対する抗体およびその使用
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
IN2014KN00848A (sh) 2012-02-01 2015-10-02 Compugen Ltd
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
JP6539585B2 (ja) 2013-02-01 2019-07-03 デンドロサイト バイオテック ピーティーワイ リミテッド 抗ｃｄ８３抗体及びその使用
JP6545105B2 (ja) 2013-02-07 2019-07-17 シーエスエル、リミテッド Ｉｌ−１１ｒ結合タンパク質及びその使用
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
LT2984108T (lt) 2013-04-09 2017-11-10 Lykera Biomed, S.A. Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP2876114A1 (en) 2013-11-25 2015-05-27 Consejo Superior De Investigaciones Científicas Antibodies against CCR9 and applications thereof
TR201900665T4 (tr) 2013-11-28 2019-02-21 B Creative Sweden Ab Diyabetik nefropatinin tedavi yöntemi.
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
KR20160096194A (ko) 2013-12-18 2016-08-12 씨에스엘 리미티드 상처 치료 방법
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US10774387B2 (en) 2014-05-19 2020-09-15 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
EP3177366A4 (en) * 2014-08-08 2018-04-04 Pharmacyclics LLC Bruton's tyrosine kinase inhibitor combinations and uses thereof
EP3186393A4 (en) 2014-08-25 2018-01-10 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
EP3209695A4 (en) 2014-10-23 2018-05-30 DendroCyte BioTech Pty Ltd Cd83 binding proteins and uses thereof
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
CN105628935A (zh) * 2016-03-01 2016-06-01 广东医学院附属医院 一种检测人尿中cd80的试剂盒
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
JP7051826B2 (ja) 2016-09-23 2022-04-11 シーエスエル、リミテッド 凝固因子結合タンパク質及びその使用
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
WO2018192974A1 (en) 2017-04-18 2018-10-25 Université Libre de Bruxelles Biomarkers and targets for proliferative diseases
KR20200067158A (ko) 2017-10-18 2020-06-11 씨에스엘 리미티드 인간 혈청 알부민 변이체 및 이의 용도
AU2019237215B2 (en) 2018-03-23 2023-11-02 Université Libre de Bruxelles Wnt signaling agonist molecules
US20210238238A1 (en) 2018-05-16 2021-08-05 Csl Limited Soluble complement receptor type i variants and uses thereof
JP7457330B2 (ja) * 2018-12-07 2024-03-28 小野薬品工業株式会社 免疫抑制剤
EP4182475A2 (en) 2020-07-17 2023-05-24 Onena Medicines S.L. Antibodies against lefty proteins
WO2023089131A1 (en) 2021-11-19 2023-05-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5045469A (en) * 1988-10-27 1991-09-03 Mycogen Corporation Novel bacillus thuringiensis isolate denoted B. T. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5304635A (en) * 1990-03-12 1994-04-19 University Of Southern California Antigen specifically expressed on the surface of B cells and Hodgkin's cells
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
DK0605442T3 (da) 1991-07-25 2003-08-04 Idec Pharma Corp Rekombinante antistoffer til human terapi
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
WO1994028912A1 (en) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
EP0721469B1 (en) 1993-09-02 2000-01-05 Trustees of Dartmouth College Anti-gp39 antibodies and uses therefor
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
BR9713498A (pt) 1996-11-08 2000-02-29 Idec Pharma Corp Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40

Also Published As

Publication number Publication date
ATE384125T1 (de) 2008-02-15
EP1914301A1 (en) 2008-04-23
DE69637408D1 (de) 2008-03-06
NZ311904A (en) 1999-09-29
PT837927E (pt) 2008-04-28
US7323170B2 (en) 2008-01-29
AU6331296A (en) 1996-12-30
US6709654B1 (en) 2004-03-23
US20050129688A1 (en) 2005-06-16
AU707023B2 (en) 1999-07-01
CA2223532C (en) 2010-11-09
NO328554B1 (no) 2010-03-22
AR001288A1 (es) 1997-10-08
CN100379855C (zh) 2008-04-09
IL122370A0 (en) 1998-06-15
CN101367877A (zh) 2009-02-18
DE69637408T2 (de) 2009-01-15
US6113898A (en) 2000-09-05
US6893638B2 (en) 2005-05-17
EP0837927B1 (en) 2008-01-16
CO4480111A1 (es) 1997-07-09
IL122370A (en) 2000-07-26
CA2223532A1 (en) 1996-12-19
MY136224A (en) 2008-08-29
NO975598D0 (no) 1997-12-03
WO1996040878A1 (en) 1996-12-19
AR053814A2 (es) 2007-05-23
JPH11508764A (ja) 1999-08-03
EP0837927A4 (en) 2000-01-05
NO975598L (no) 1998-02-09
EP0837927A1 (en) 1998-04-29
CN1192779A (zh) 1998-09-09
KR100496307B1 (ko) 2005-11-25
DK0837927T3 (da) 2008-05-13
ES2301169T3 (es) 2008-06-16
HK1015413A1 (en) 1999-10-15
UY24256A1 (es) 1996-06-18
JP4242451B2 (ja) 2009-03-25
BR9609035A (pt) 1999-07-06
ZA964547B (en) 1997-01-24
US20010024648A1 (en) 2001-09-27
SA96170473B1 (ar) 2005-07-31
KR19990022650A (ko) 1999-03-25

Similar Documents

Publication Publication Date Title
YU35996A (sh) Monoklonalna antitela specifična na humani b7.1 i/ili b7.2, njihovi primatizovani oblici i farmaceutski preparati koji ih sadrže
Graus et al. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies.
DK0627002T3 (da) Kloning og ekspression af humaniserede monoklonale antistoffer mod human interleukin-4
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
EP1174440A1 (en) A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US20070259387A1 (en) Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof
AR003423A1 (es) Anticuerpos monoclonales humanos de alta afinidad especificos de la proteina- f del rsv, celulas eucarioticas transfectadas; secuencia de adn y vector de expresion que lo codifican; metodo que utiliza los anticuerpos; una composicion farmaceutica que los contiene; metodo para detectar rsv y un kit de ensayo.
HUP0401560A2 (hu) Terápiás kötőmolekulák
Newman Selective blockade of human natural killer cells by a monoclonal antibody.
AR045765A1 (es) Moleculas de union a cd45 y uso terapeutico
ES2321687T3 (es) Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
Waldor et al. Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody.
Forni et al. Expression of V-region-like determinants on Ig-negative precursors in murine fetal liver and bone marrow
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
Gearhart Non-sequential expression of multiple immunoglobulin classes by isolated B-cell clones
Rocca-Serra et al. The limited diversity of the mouse gamma-chains anti-GAT repertoire does not seem to be noticeably amplified upon class switch.
MX9709541A (es) Anticuerpos monoclonales de mono, especificos para las formas primatizadas de b7.1 y/o b7.2 humanos y composiciones farmaceuticas.
Dehghanpisheh et al. Retrovirally induced mouse anti‐TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens
Ju et al. The B cell immune response to an idiotype-inducing peptide epitope can be inhibited by immunodominance of a neighboring epitope.
Claflin Clonal nature of the immune response to phosphorylcholine. VIII. Evidence that antibodies bearing T15 idiotypic determinants in Ighj mice comprise a family of antibodies
MY104917A (en) Monoclonal antibodies and methods for diagnosis of phytophora infection
Deem et al. Role of the CD45 (T-200) molecule in anti-CD3-triggered T cell-mediated cytotoxicity
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung